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be broken up into three components: costs associated to the
preparation time (71%), material costs (27%) and the waste
management costs (2%). For 100 patients treated receiving 10
cycles of chemotherapy, this represents a total saving of €1040.
CONCLUSIONS: Using oxaliplatin concentrated solution form
represented a time saving and an economic beneﬁt for the hos-
pital pharmacist. In addition, this new solution form increases
the safety aspects by reducing risk of preparation errors and risk
of cytotoxic drug exposure for manipulators. It would be inter-
esting to conﬁrm those results in a multi-centric analysis.
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OBJECTIVES: OPTIMOX1 randomised study demonstrated
that FOLFOX7 with oxaliplatin stop-and-go could be safely
used and achieved the same efﬁcacy results as standard treatment
FOLFOX 4 in advanced colorectal cancer. The median progres-
sion free-survival and survival times were 9.0 and 19.3 months,
respectively in FOLFOX4 arm compared with 8.7 and 21.2
months, respectively in FOLFOX7 arm (p = not signiﬁcant).
FOLFOX 7 stop and go strategy was associated with reduced
risk of grade 3 to 4 toxicity [Tournigand, JCO 2006;24:394].
The main objective was to perform an economic evaluation of
FOLFOX7 stop-and-go compared with FOLFOX4 regimen in
advanced colorectal cancer. METHODS: A cost-minimisation
analysis has been conducted based on the efﬁcacy results of
OPTIMOX1 study. The perspective was that of the third party
payer and included only direct medical costs: chemotherapy, hos-
pitalisation and side effects management. The horizon time was
from inclusion until patient death. Sensitivity analyses were 
performed on drug costs and full/day hospitalisation rates.
RESULTS: Hospitalisation costs per patient were the main driver
for cost. Hospitalisation represented €6595 in FOLFOX7 arm
vs. €10,522 in FOLFOX4 arm reﬂecting the decrease of number
of hospitalisation days (p < 0.001). Chemotherapy costs per
patient were comparable in each treatment arm despite higher
doses of oxaliplatin with FOLFOX7 (€6870) compared to
FOLFOX4 (€7047) (p = 0.30). The cost of side effects manage-
ment appeared very low in both groups, compared to hospitali-
sation and drug costs with €271 and €382 (p = 0.11) for
FOLFOX4 and FOLFOX7 respectively. The mean total cost per
patient was higher in FOLFOX4 arm than in FOLFOX7 arm
with €17,841 versus €13,847 respectively (p < 0.001). CON-
CLUSION: The FOLFOX7 regimen with intermittent oxali-
platin treatment (stop-and-go) is cost saving compared with
FOLFOX4 regimen.
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OBJECTIVES: To compare costs of navelbine-cisplatine (PN)
versus gemcytabine-cisplatin (PG) recommended in non small
cell lung cancer (NSCLC) treatment in Poland. METHODS:
Data of health outcome, adverse event rates, speciﬁcation for
each regimen and the number of cycles derived from the pub-
lished head-to-head clinical trial (Martoni & co. European
Journal of Cancer 41, s.81–92, 2005). Only direct medical cost
were assessed such as diagnostic tests, cytostatics and additional
medication used and hospitalization (cost of blood tests and
antiemetics included). The payer’s perspective were chosen.
Information of value of health resources consumed were derived
from the medical valuation system used by National Fund of
Health in 2006. All cost were in polish zloty (in 2006: 1 euro =
3,95 zloty). RESULTS: Because there were no statistically sig-
niﬁcant differences in effectiveness between analyzed regimens,
the cost-minimisation analysis were performed. The average
total costs per patient was 10,452 zl for PN and 31,478 zl for
PG. However in both regimens the main part of total costs were
cost of gemcytabine (60%) or navelbine (55%), the nominal
value amount 5668 zl for navelbine and 18,860 zl for gem-
cytabine. In PG scheme 7% were cost of hospitalization and
4.5% cost of ADR treatment. In PN scheme 21,5% were cost of
hospitalization and 15.4% cost of ADR treatment. The high cost
of ADR management for PN were caused by cost of neutrope-
nia treatment. CONCLUSIONS: Despite of high percentage of
ADR management in PN, our analysis showed that total cost 
of chemotherapy with this scheme is three times less than
chemotherapy with PG. So the PN regimen should be recom-
mended as cost saving for patients with advanced NSCLC, spe-
cially as a palliative chemotherapy.
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OBJECTIVES: The oral formulation of ﬂudarabine phosphate is
equivalent to the IV formulation in terms of clinical efﬁcacy, in
previously untreated B-CLL. The objective of this evaluation is
to perform a cost minimization analysis. METHODS: To
conduct this evaluation the following parameters were consid-
ered: acquisition value of the IV and oral ﬂudarabine by the
public health system (PHS); resources consumption for IV ﬂu-
darabine application; toxicity proﬁle of the two presentations
based on literature data; adverse events management and their
resource consumption according to the Inca; PHS reimbursement
for the patients hospitalized with LCC; an index patient with
1.69 m2 body surface area and 60 years old; oral and IV ﬂu-
darabine dose of 40 mg/m2 and 25 mg/m2 respectively. The treat-
ment cost of a given adverse event was considered to be the same
irrespectively to the ﬂudarabine presentation. RESULTS:
Although oral ﬂudarabine presented a lower cost per mg in com-
parison to the IV formulation (R$9.85 vs. R$10.20) the total
drug cost for the whole treatment is greater for the oral formu-
lation than for IV (R$20,676.60 vs. R$15,300.00). However
considering that the administration cost per cycle of the IV 
formulation is R$956,80 the overall cost of IV ﬂudarabine
becomes higher than the oral formulation (R$22,150.78 vs.
R$23,160.31). The cost of the treatment of each considered
adverse event for oral and IV ﬂudarabine were respectively:
infection (339.72 vs. 519.99); neutropenia (962.79 vs. 1187.75),
anemia (106.02 vs. 222.74), diarrhea (11.97 vs. 0.00), nausea
(2.25 vs. 7.11) and thrombocytopenia (52.47 vs. 182.05).
Overall IV ﬂudarabine costs 4.56% more than its oral formula-
tion. CONCLUSIONS: This preliminary analysis shows that oral
ﬂudarabine has lower total cost per patient with similar efﬁcacy
to IV ﬂudarabine with lower adverse events and administration
costs. A cost effectiveness analysis should conﬁrm these promis-
ing data.
